Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option

SIMPLE SUMMARY: Due to improved selectivity and favorable toxicity profiles, the next-generation Bruton’s tyrosine kinase inhibitors (BTKis) are replacing ibrutinib in the treatment of B-cell malignancies including chronic lymphocytic leukemia (CLL). While efficacy between different BTKi agents is p...

Descripción completa

Detalles Bibliográficos
Autores principales: Molica, Stefano, Tam, Constantine, Allsup, David, Polliack, Aaron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377923/
https://www.ncbi.nlm.nih.gov/pubmed/37509398
http://dx.doi.org/10.3390/cancers15143737

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377923/
https://www.ncbi.nlm.nih.gov/pubmed/37509398
http://dx.doi.org/10.3390/cancers15143737

Ejemplares similares